TY - JOUR
T1 - Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance
AU - Augustine, Alicia H.
AU - Lowenstein, Lisa M.
AU - Harris, William S.
AU - Shearer, Gregory C.
AU - Block, Robert C.
N1 - Funding Information:
AA and LL were supported by the National Heart Lung and Blood Institute Preventive Cardiology T32 granted to Thomas A. Pearson of the University of Rochester ( 5 T32 HL007937 ). Measurements of lipoprotein fatty acids were supported by a grant from GlaxoSmithKline ( LVZ 122790 ). The original trial was supported by the National Institute of Health ( 5 R01 DK061486 ). Abbott (Niaspan ® ) and GlaxoSmithKline (Lovaza ® ) provided the drugs used in this study.
PY - 2014
Y1 - 2014
N2 - Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.
AB - Introduction: The effects of dietary fatty acid supplementation on lipoprotein fatty acid composition have rarely been described. Patients and methods: Sixty-one overweight and obese adults with dyslipidemia and insulin resistance were randomized to placebo, 2. g/day extended-release nicotinic acid (ERN), 4. g/day prescription omega-3 fatty acid ethyl ester (P-OM3), or combination therapy for 16 weeks. Lipoprotein fatty acid composition was analyzed by gas chromatography pre- and post-treatment. Results: Treatment with P-OM3 or combination, but not ERN, increased proportions of eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid, and reduced those for arachidonic acid in all lipoprotein fractions, with greatest impact in the high-density lipoprotein fraction. P-OM3-induced changes in eicosapentaenoic acid within low-density lipoproteins and very low-density lipoproteins were associated with beneficial effects on mean arterial pressure and pulse pressure. Conclusions: P-OM3 supplementation, with or without ERN, was associated with differentially altered lipoprotein fatty acid composition and improved blood pressure parameters.
UR - https://www.scopus.com/pages/publications/84895906372
UR - https://www.scopus.com/pages/publications/84895906372#tab=citedBy
U2 - 10.1016/j.plefa.2013.12.003
DO - 10.1016/j.plefa.2013.12.003
M3 - Article
C2 - 24378016
AN - SCOPUS:84895906372
SN - 0952-3278
VL - 90
SP - 69
EP - 75
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
IS - 2-3
ER -